MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
$22,196K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
20 4,745
Depreciation and amortization
1,115 1,893
Share-based compensation expense
4,919 9,510
Acquired in-process research & development expense
20,000 -
Other adjustments
-262 -786
Accounts receivable
1,813 6,534
Inventories
681 3,361
Prepaid expenses and other current assets
-842 2,404
Accounts payable & other current liabilities
2,289 2,778
Accrued expenses
-3,572 2,077
Other assets and liabilities
652 3,453
Net cash provided by (used in) operating activities
22,205 4,465
Purchases of property and equipment
9 181
Proceeds from sales of marketable securities
11,800 45,938
Purchases of marketable securities
5,224 41,694
Upfront license payment for acquired in-process research & development
15,000 -
Net cash (used in) provided by investing activities
-8,433 4,063
Proceeds from issuance of shares off the at-the-market offering program
0 0
Proceeds from stock option exercises and employee share purchase plan
2,507 1,672
Net cash provided by financing activities
2,507 1,672
Effect of foreign currency exchange rate changes on cash and cash equivalents
132 1,831
Net change in cash and cash equivalents
16,411 12,031
Cash and cash equivalents at beginning of period
51,371 -
Cash and cash equivalents at end of period
79,813 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

AVADEL PHARMACEUTICALS PLC (AVDL)

AVADEL PHARMACEUTICALS PLC (AVDL)